After adjustments for age and tumor characteristics (model 1, 0–5 years), there was moderate evidence that patients with AR+ER− tumors had higher BCM during the short-term follow-up compared to patients with AR+ER+ tumors. This evidence concerns the gene ESR1 and neoplasm.